Hasnain Faheem — SEC insider filings
SEC reporting owner CIK 1352620. 36 insider filings on record with FilingPulse; latest filed 2026-11-09.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2020-10-14 to 2026-11-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 5 filings — 1,496,579 shares, $3,550,654 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 74,889 shares, $487,690 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
- Largest priced transaction: purchase of 138,696 shares @ $7.21 ($999,998) in Gossamer Bio, Inc., filed 2022-07-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | President & CEO, Director | 18 | 6 legs · 1,485,788 sh · $3,250,664 | 2 legs · 42,207 sh · $196,470 | 36 |
| Mirati Therapeutics, Inc. (MRTX) | Director | 6 | 1 leg · 10,791 sh · $299,990 | — | 13 |
| Kura Oncology, Inc. (KURA) | Director | 8 | — | 2 legs · 32,682 sh · $291,220 | 8 |
| Aspen Neuroscience, Inc. (ASPE) | Executive Chair, Director | 3 | — | — | 7 |
| Nuvation Bio Inc. (NUVB) | Director | 1 | — | — | 3 |
Insider filings — Hasnain Faheem
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-09 | 4 | Aspen Neuroscience, Inc. (ASPE) | Grant/award (A): 321,672 @ $0 | EDGAR |
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) | Conversion (C): 14,913 · Conversion (C): 14,316 · Conversion (C): 7,120 · Conversion (C): 14,913 (derivative) · Conversion (C): 14,316 (derivative) · Conversion (C): 7,120 (derivative) | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) | Holdings only — no transactions reported | EDGAR |
| 2026-08-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 166 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Gossamer Bio, Inc. (GOSS) | Disposition to issuer (D): 1,680,000 (derivative) · Disposition to issuer (D): 1,540,000 (derivative) · Disposition to issuer (D): 1,312,500 (derivative) · Disposition to issuer (D): 437,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · +14 more | EDGAR |
| 2026-01-05 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 280,000 @ $0 · Grant/award (A): 1,680,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 10,000 @ $3.12 · Sale (S): 10,000 @ $10.98 | EDGAR |
| 2025-10-02 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 437,500 @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | Kura Oncology, Inc. (KURA) | Option exercise (M): 22,682 @ $6.32 · Sale (S): 22,682 @ $8 | EDGAR |
| 2025-03-06 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 1,540,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 372,000 @ $0.67 | EDGAR |
| 2024-06-07 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 23,172 @ $1.16 | EDGAR |
| 2024-01-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Disposition to issuer (D): 8,717 · Disposition to issuer (D): 6,333 · Disposition to issuer (D): 9,702 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 10,716 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2024-01-04 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 1,312,500 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 9,702 @ $58.75 | EDGAR |
| 2023-11-22 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 437,500 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Mirati Therapeutics, Inc. (MRTX) | Purchase (P): 10,791 @ $27.80 | EDGAR |
| 2023-07-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 540,176 @ $1.82 · Grant/award (A): 135,044 (derivative) @ $0.12 | EDGAR |
| 2023-06-02 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2023-03-22 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 168,683 @ $1.03 · Purchase (P): 269,389 @ $1.20 · Purchase (P): 440,500 @ $1.14 · Grant/award (A): 544,500 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 6,333 @ $0 · Grant/award (A): 10,716 (derivative) @ $0 | EDGAR |
| 2022-12-09 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 544,500 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 138,696 @ $7.21 | EDGAR |
| 2022-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2022-03-24 | 4 | Gossamer Bio, Inc. (GOSS) | Sale (S): 19,035 @ $8.91 | EDGAR |
| 2022-01-18 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 3,619 @ $0 · Grant/award (A): 5,243 (derivative) @ $0 | EDGAR |
| 2022-01-10 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2021-03-01 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 162,500 @ $0 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2021-02-26 | 4 | Nuvation Bio Inc. (NUVB) | Option exercise (M): 25,000 @ $0 · Grant/award (A): 30,000 @ $10 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2021-01-20 | 4 | Mirati Therapeutics, Inc. (MRTX) | Grant/award (A): 2,098 @ $0 · Grant/award (A): 3,064 (derivative) @ $0 | EDGAR |
| 2020-10-14 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 96,520 @ $10.36 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-13 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1352620 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs